Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30022841 | 0.88 | GABRA1 (0.33) | HDAC3HDAC1HDAC2HDAC6AAK1 | |
| SCHEMBL3006398 | 0.84 | CES2 (0.42) | RAF1BRAFCACNA1HCACNA1BCACNA1C | |
| SCHEMBL20310373 | 0.83 | MAPT (0.46) | RAF1BRAFRXFP1MAPTIKBKE | |
| SCHEMBL545623 | 0.81 | CAMK1D (0.41) | HDAC3HDAC1HDAC2HDAC6MAPT | |
| SCHEMBL4783457 | 0.81 | HDAC3 (0.40) | HDAC3HDAC1HDAC2HDAC6MAPT | |
| SCHEMBL687306 | 0.79 | RXFP1 (0.48) | RXFP1MAPTIKBKELMNAP2RX1 | |
| SCHEMBL3200118 | 0.78 | GAA (0.42) | RXFP1LMNAGAA | |
| SCHEMBL10282363 | 0.76 | EPHX2 (0.39) | MAPTLMNAPOLBAPLNR | |
| SCHEMBL17040319 | 0.76 | APLNR (0.38) | RXFP1AAK1APLNRGAA | |
| SCHEMBL10200705 | 0.76 | CACNA1H (0.49) | CACNA1HCACNA1BCACNA1CHDAC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530193-B2 | Kinase inhibitors | THE UNIVERSITY OF MANCHESTER (GB) | 2022-12-20 | — | — | US | disclosed |
| US-10562899-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BEIGENE, LTD. (KY) | 2020-02-18 | — | — | US | disclosed |
| US-20190144446-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2019-05-16 | — | — | US | disclosed |
| US-10208038-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BEIGENE, LTD. (KY) | 2019-02-19 | — | — | US | disclosed |
| EP-3013798-B1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEIGENE LTD (KY) | 2018-06-27 | — | — | EP | disclosed |
| US-9920055-B2 | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors | BEIGENE, LTD. (KY) | 2018-03-20 | — | — | US | disclosed |
| US-20170233391-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2017-08-17 | — | — | US | disclosed |
| US-9670203-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BEIGENE, LTD. (KY) | 2017-06-06 | — | — | US | disclosed |
| US-20160368914-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2016-12-22 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007067444-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368914-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885CACNA1H 4628/4885 |
| US-20190144446-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885CACNA1H 4628/4885 |
| US-11530193-B2 | Kinase inhibitors | CAMKK2, CAMK1, CAMKK1 | RAF1 152/4885BRAF 219/4885CACNA1H 1995/4885 |
| US-20170233391-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885CACNA1H 4628/4885 |
| US-10208038-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885CACNA1H 4628/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | RAF1 198/4885BRAF 215/4885CACNA1H 4399/4885 |
| US-10562899-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885CACNA1H 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.